Juq-123 Extra Quality -
JUQ-123: A Novel Dual Inhibitor Targeting JAK2 and USP7 Demonstrates Synergistic Anti-Tumor Efficacy in Preclinical Models of Acute Myeloid Leukemia
Abstract Background: Acute Myeloid Leukemia (AML) remains a hematological malignancy with poor prognosis, particularly in patients with high-risk genetic mutations. Constitutive activation of the JAK-STAT pathway and the dysregulation of deubiquitinases (DUBs), specifically USP7, are two critical mechanisms driving AML pathogenesis and chemoresistance. Methods: We describe the preclinical characterization of JUQ-123, a first-in-class, rationally designed small molecule that acts as a dual inhibitor of JAK2 and USP7. In vitro assays were conducted to evaluate binding affinity, kinase selectivity, and DUB inhibitory activity. Cellular proliferation, apoptosis, and cell cycle analyses were performed on a panel of AML cell lines and primary patient-derived xenograft (PDX) cells. In vivo efficacy was assessed using systemic AML murine models. Results: JUQ-123 exhibited high affinity for both the ATP-binding pocket of JAK2 (IC50 = 12 nM) and the catalytic domain of USP7 (IC50 = 35 nM). In AML cell lines, JUQ-123 induced robust G1 cell cycle arrest and apoptosis, outperforming monotherapies targeting either JAK2 (Ruxolitinib) or USP7 (FTX-671) alone. Mechanistically, dual inhibition resulted in the concurrent suppression of STAT5 phosphorylation and the stabilization of the tumor suppressor p53. In vivo, oral administration of JUQ-123 led to significant leukemic burden reduction and prolonged overall survival without inducing systemic toxicities. Conclusions: JUQ-123 represents a highly promising therapeutic strategy. By simultaneously disrupting JAK-STAT signaling and restoring p53 tumor suppressor activity via USP7 inhibition, JUQ-123 circumvents compensatory resistance mechanisms, warranting its rapid translation into early-phase clinical trials for high-risk AML.
JUQ-123 — Overview
What it is: JUQ-123 is a modular, enterprise-grade solution designed to streamline [primary purpose — e.g., data ingestion, device management, access control]. It integrates with existing infrastructure and scales from pilot to production. JUQ-123
Is it a:
3.2. Ferroelectric Properties
Figure 2a displays a well‑saturated P‑E hysteresis loop at 300 K with Pₛ ≈ 9 µC cm⁻², coercive field E_c ≈ 120 kV cm⁻¹, and remanent polarization Pr ≈ 7.5 µC cm⁻². The loops retain their shape up to 425 K, above which the material transitions to a paraelectric phase (T_c ≈ 438 K). JUQ-123: A Novel Dual Inhibitor Targeting JAK2 and
1. Introduction Actin filaments (F-actin) are polar polymers essential for maintaining cell shape and facilitating movement. The regulation of actin turnover is tightly controlled by a vast array of actin-binding proteins (ABPs). While mechanisms involving severing proteins like cofilin and capping proteins like CapZ are well-documented, the precise regulation in specific membrane ruffles and lamellipodia remains complex. In vitro assays were conducted to evaluate binding
System Compatibility: Before integration, verify that the existing power delivery systems meet the specific voltage and current requirements to prevent unexpected resets or hardware wear.
As we dive deeper into the mystery of "JUQ-123", we begin to uncover some fascinating possibilities. Could it be a: